Douglas Sawyer
Faculty Member
Last active: 7/21/2014

Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Galindo CL, Ryzhov S, Sawyer DB
Curr Heart Fail Rep. 2014 11 (1): 40-9

PMID: 24234399 · PMCID: PMC3975684 · DOI:10.1007/s11897-013-0176-2

The beta isoform of Neuregulin-1 (NRG-1β), along with its receptors (ErbB2-4), is required for cardiac development. NRG-1β, as well as the ErbB2 and ErbB4 receptors, is also essential for maintenance of adult heart function. These observations have led to its evaluation as a therapeutic for heart failure. Animal studies and ongoing clinical trials have demonstrated beneficial effects of two forms of recombinant NRG-1β on cardiac function. In addition to the possible role for recombinant NRG-1βs as heart failure therapies, endogenous NRG-1β/ErbB signaling appears to play a role in restoring cardiac function after injury. The potential mechanisms by which NRG-1β may act as both a therapy and a mediator of reverse remodeling remain incompletely understood. In addition to direct effects on cardiac myocytes NRG-1β acts on the vasculature, interstitium, cardiac fibroblasts, and hematopoietic and immune cells, which, collectively, may contribute to NRG-1β's role in maintaining cardiac structure and function, as well as mediating reverse remodeling.

MeSH Terms (10)

Biomarkers Cardiovascular Agents Cardiovascular Diseases ErbB Receptors Heart Failure Humans Neuregulin-1 Recombinant Proteins Signal Transduction Ventricular Remodeling

Connections (2)

This publication is referenced by other Labnodes entities: